Longevity · Senolytic

FOXO4-DRI

FOXO4-DRI is a synthetic peptide designed to selectively induce apoptosis in senescent cells, a foundational mechanism of biological aging. Heavily studied in mouse models of aging.

Category: Longevity Last updated 2026-06-19

FOXO4-DRI at a glance

FOXO4-DRI is a synthetic peptide designed to selectively induce apoptosis in senescent cells, a foundational mechanism of biological aging. Heavily studied in mouse models of aging. Mechanism: Senolytic peptide. Typical route: Intraperitoneal (animal); SC (human protocols). FDA status: Not FDA-approved. Available through research-chemical suppliers; clinical-grade compounded versions are uncommon. Human safety and efficacy data are essentially nonexistent.

Drug classSenolytic peptide

Half-lifeShort (hours)

RouteIntraperitoneal (animal); SC (human protocols)

Animal dosing5 mg/kg, intermittent

FDA statusNot approved

Available throughResearch suppliers

Mechanism of action

FOXO4-DRI disrupts the interaction between FOXO4 and p53 in senescent cells, releasing p53 to trigger apoptosis selectively in cells that have entered senescence. Healthy cells are spared. The result is a 'senolytic' clearance of accumulated senescent cells.

Dosing reference

Animal-protocol dosing: 5 mg/kg intraperitoneal, three doses over five days, repeated every several weeks. Human dosing is not standardized; clinical-trial data is absent.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Available through research-chemical suppliers; clinical-grade compounded versions are uncommon. Human safety and efficacy data are essentially nonexistent.

U.S. telehealth providers that work with FOXO4-DRI

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.

Read review →

#3 of 4

BreezeMeds

68/100v3.0 six-pillar rubric

Starting at $199/mo. BreezeMeds is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.

Read review →

#4 of 4

Hone Health

80/100v3.0 six-pillar rubric

Starting at $149/mo. Hone Health is one of the providers covered in our editorial directory that dispenses or coordinates FOXO4-DRI.

Read review →

Related longevity peptides

Browse the full Longevity category →

Frequently asked questions about FOXO4-DRI

Does FOXO4-DRI work in humans?

Human clinical-trial data is essentially absent. Mouse-model results are striking (reduced frailty, restored kidney and coat function) but cross-species extrapolation in senolytics has historically been imperfect.

Is FOXO4-DRI safe?

Long-term safety in humans is unknown. Senolytic mechanisms can theoretically have off-target effects on stem cells. We do not recommend self-experimentation outside of monitored clinical trials.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing